Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-Radiation + TriAb/TriGem Vaccines in SCLC
NCT00045617Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Jan 2003
- Primary completion
- May 2003
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 11D10 anti-idiotype in small cell lung cancer (SCLC), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival up to 5 years. Started Jan 2003; status: terminated.
02
Drugs
11D10 anti-idiotype
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00045617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045617.